US watchdog warns on fitness stimulant

April 27, 2012 in Medications

The US Food and Drug Administration on Friday questioned the safety of DMAA, a stimulant used in dietary supplements, alleging that marketers were illegally selling the chemical.

Popular with fitness buffs seeking an edge or weight loss, the brands include Napalm, Code Red, Hemo Rage Black, Nitric Blast and Jack3D.

The FDA said it issued warning letters to 10 manufacturers and distributors of containing the ingredient for failing to submit evidence of the safety of their products.

"Before marketing products containing DMAA, manufacturers and distributors have a responsibility under the law to provide evidence of the safety of their products. They haven't done that and that makes the products adulterated," said Daniel Fabricant, director of the FDA's Dietary Supplement Program.

In the warning letters, the FDA also said it was not aware of evidence or history of use to indicate that DMAA is safe.

Dimethylamylamine, also referred to as "geranium extract," is often touted as a "natural" stimulant, the FDA said.

"The agency additionally warned the companies that synthetically produced DMAA is not a 'dietary ingredient' and, therefore, is not eligible to be used as an active ingredient in a dietary supplement," the agency said.

The FDA letters raised concerns that DMAA is known to narrow blood vessels and arteries, which can lead to and .

The federal agency said it had received 42 adverse reports on products containing DMAA, including and death.

In December, the Army Times reported the Defense Department had ordered an end to on-base sales of a number of workout supplements containing DMAA, pending a review of its safety.

The Pentagon worried that the substance may have contributed to the deaths of two soldiers who had heart attacks during physical training after using DMAA products, as well as the cases of three soldiers and two Marines who collapsed during heavy exercise, the specialty newspaper reported.

The FDA said the firms have 15 business days to respond with the specific steps they will take to address the issues in the warning letters.

The 10 companies warned are: Exclusive Supplements, Fahrenheit Nutrition, Gaspari Nutrition, iSatori Global Technologies, Muscle Warfare, MuscleMeds Performance Technologies, Nutrex Research, SEI Pharmaceuticals, SNI, and USP Labs.

(c) 2012 AFP

not rated yet  

Filter


Move the slider to adjust rank threshold, so that you can hide some of the comments.


Display comments: newest first

kochevnik
Apr 28, 2012

Rank: not rated yet
Forget sniper fire and IDEs. The DMAA is out to get you! And keep burning that $500/gallon gasoline courtesy of Halliburton.
Rank not rated yet
Related Stories
Relevant PhysicsForums posts

More news stories

Acne pill benefits outweigh blood clot risk: EU agency

Europe's medicines watchdog said Friday the benefits of acne drug Diane-35, also widely used as a contraceptive, outweigh the risk of developing blood clots in the veins—when correctly prescribed.

Medications created May 17, 2013 | popularity not rated yet | comments 0

First influenza vaccine brought to clinical testing

Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their ...

Medications created May 17, 2013 | popularity 5 / 5 (1) | comments 0

Aspirin not always best treatment for many individuals

(Medical Xpress)—An aspirin a day may not always keep heart disease away, say two University of Florida cardiologists. But a new algorithm they have developed outlines factors physicians should weigh as ...

Medications created May 16, 2013 | popularity 3.5 / 5 (2) | comments 0 | with audio podcast

FDA: lower ambien's dose to prevent drowsy driving

(HealthDay)—The U.S. Food and Drug Administration has approved new, lower-dose labeling for the popular sleep drug Ambien (zolpidem) in an effort to cut down on daytime drowsiness that could be a hazard ...

Medications created May 15, 2013 | popularity not rated yet | comments 0

Simponi approved for ulcerative colitis

(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.

Medications created May 15, 2013 | popularity not rated yet | comments 0


Researchers identify a potential new risk for sleep apnea: Asthma

Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...

New theory on genesis of osteoarthritis comes with successful therapy in mice

Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...

Computational tool translates complex data into simplified 2-dimensional images

In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...

Study finds that sleep apnea and Alzheimer's are linked

A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.

'Gap' for HIV vaccine efforts after latest setback

The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.

Ginger compounds may be effective in treating asthma symptoms

Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the ...